Literature DB >> 14674007

Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.

Kai U Ulbricht1, Matthias Stoll, Janine Bierwirth, Torsten Witte, Reinhold E Schmidt.   

Abstract

Sarcoidosis is a multisystemic disorder histologically characterized by a noncaseating granulomatous inflammatory process. The etiology remains unclear, but tumor necrosis factor alpha seems to play a crucial role. Herein we describe a patient with severe sarcoidosis involving the lung and liver. Various treatment regimens with azathioprine, methotrexate, cyclophosphamide, and pentoxifylline failed to control the disease. Therefore, salvage therapy with infliximab was commenced. Arthritis and pulmonary and liver involvement improved. We were then able to taper the corticosteroid treatment to a lower-dose regimen with no need for additional immunosuppressive treatment. To our knowledge, this is the first reported case of successful treatment of multiorgan sarcoidosis that was previously resistant to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14674007     DOI: 10.1002/art.11357

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

1.  An unusual case of granulomatous lung disease. A clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Authors:  Deborah Alpert; Douglas B Flieder; Doruk Erkan; Anne R Bass
Journal:  HSS J       Date:  2006-09

2.  Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.

Authors:  Tobias Lahmer; Andreas Knopf; Ines Lanzl; Uwe Heemann; Klaus Thuermel
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

3.  Treatment of therapy-resistant sarcoidosis with adalimumab.

Authors:  José Luis Callejas-Rubio; Norberto Ortego-Centeno; Lourdes Lopez-Perez; Maria Nicolas Benticuaga
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

Review 4.  Bone health issues in sarcoidosis.

Authors:  Nadera J Sweiss; Elyse E Lower; Peter Korsten; Timothy B Niewold; Murray J Favus; Robert P Baughman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

5.  Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report.

Authors:  Supen R Patel
Journal:  J Med Case Rep       Date:  2009-07-29

Review 6.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 7.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Mizoribine for renal sarcoidosis: effective steroid tapering and prevention of recurrence.

Authors:  Shuichi Ito; Tomonori Harada; Tomoko Nakamura; Tomoyuki Imagawa; Kiyotaka Nagahama; Takeshi Sasaki; Shuichiro Fujinaga; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2008-09-13       Impact factor: 3.714

9.  Cardiac sarcoidosis responding to monotherapy with infliximab.

Authors:  Imad Uthman; Zahi Touma; Maurice Khoury
Journal:  Clin Rheumatol       Date:  2007-03-30       Impact factor: 2.980

10.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.